期刊文献+

脂质过氧化物酶体增殖物激活受体α在人肝癌多药耐药中的作用 被引量:3

Role of peroxisome proliferator-activated receptor α in multidrug resistance of human hepatocellular carcinoma
原文传递
导出
摘要 目的研究脂质过氧化物酶体增殖物激活受体α(peroxisome proliferator-activated receptor α,PPARα)在人肝癌多药耐药中的作用机制。方法利用透射电镜观察人肝癌多药耐药 (multidrug resistance,MDR)细胞HepG2/ADM及其亲本细胞HepG2的超微结构;荧光定量PCR技术检测PPARα mRNA在两种细胞系中的表达水平;免疫印记法检测PPARα蛋白的在两种细胞中的表达情况。结果人肝癌多药耐药细胞与其亲本细胞相比,耐药细胞的核膜上绒毛样突起增多,胞浆内有大量空泡,粗面内质网增多;HepG2/ADM细胞的PPARα mRNA表达和蛋白表达均有下降。结论PPARα与HepG2/ADM细胞的MDR现象有关,PPARα表达下调可能是肿瘤细胞MDR形成的机制之一。 Objective To study the role of PPARα gene in human hepatocellular carcinoma. Methods Transmission elctron microscopy was used to study the morphologic differences between the MDR cell line HepG2/ADM and its mother cell line HepG2 ; Real-time RT-PCR and Western blotting were used to check the expression of PPARα in mRNA level and protein level in the two cell lines respectively. Results Transmission elctron microscopy showed that the HepG2/ADM cells had more viliformed maculas on their nuclear memberanes, more vacuoles in their cytoplasmas, more rough endoplastic reticulums; the PPARα gene was down regulated in the HepG2/ADM cells. Conclusion PPARα is related with the muhidrug resistance phenomenon in the HepG2/ADM cells. The down regulation of PPARα may be one of the mechanisms conferring the forming of MDR in tumor cells.
出处 《中华普通外科杂志》 CSCD 北大核心 2006年第2期145-147,共3页 Chinese Journal of General Surgery
基金 国家青年自然科学基金资助项目(30400431) 卫生部临床重点学科基金资助项目(2001-321)
关键词 肝细胞 基因表达 脂质过氧化物体增殖物激活受体α 多药耐药 Carcinoma, hepatocellular Gene expression Peroxisome proliferator-activated receptor α Muhidrug resistance
  • 相关文献

参考文献6

二级参考文献2

  • 1Roth J,Goebeler M,Ludwig S,et al.Homocysteine inhibits tumor necrosis factor-induced activation of endothelium via modulation of nuclear factor-kb activity[].Biochimica et Biophysica Acta.2001
  • 2刘景丰,陈孝平.人肝癌多药耐药细胞模型的建立[J].肝胆外科杂志,1999,7(2):153-155. 被引量:11

共引文献39

同被引文献19

  • 1王其,陈孝平,张万广,张必翔.人肝癌HepG2多药耐药细胞系的部分生物学性状研究[J].中华实验外科杂志,2004,21(5):538-540. 被引量:40
  • 2邹健,冉志华,黄美兰,萧树东.人结肠癌羟基喜树碱耐药细胞株SW1116/HCPT的建立与鉴定[J].胃肠病学,2006,11(6):327-331. 被引量:10
  • 3黄美兰,冉志华,邹健,萧树东.羟基喜树碱耐药结肠癌细胞株SW1116/HCPT肿瘤耐药相关基因的表达[J].肿瘤,2007,27(2):96-100. 被引量:3
  • 4John B,Enright AJ,Aravin A,et al.Human MicroRNA targets.PLoS Biol,2004.2:e363.
  • 5John B,Sander C,Marks DS.Prediction of human mieroRNA targets.Methods Mol Biol,2006,342:101-113.
  • 6Schinner S,Kr(a)fitzner R,Baun D,et al.Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazoli djnedione oral antidiabetic drugs.Br J Pharmaeol,2009,157:736-745.
  • 7Sarruf DA,Yu F,Nguyen HT,et al.Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis.Endocrinology,2009,150:707-712.
  • 8Oshio H,Abe T,Onogawa T,et al.Peroxisome proli ferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines.J Gastroenterol,2008,43:538-549.
  • 9Yokoyama Y,Xin B,Shigeto T,et al.Clofibric acid.a peroxisome proliferator-activated receptor alpha ligand,inhibits growth of human ovarian cancer.Mol Cancer Ther,2007,6:1379-1386.
  • 10Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther,2004,11 : 1170-1174.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部